COMMUNIQUÉS West-GlobeNewswire

RadNet’s Wholly-Owned Subsidiary, DeepHealth, to Use CARPL.ai's Platform to Develop a New AI Control System for Clinical AI Performance and Safety
01/12/2024
DeepHealth and CARPL.ai have established a strategic collaboration to create a unique Artificial Intelligence (AI) control system for image interpretation to ensure AI scalability, performance monitoring, and safety, [...]
Siemens Healthineers and RadNet’s Wholly-Owned Subsidiary, DeepHealth, to Collaborate Around Elevating Ultrasound Workflows with AI-Powered SmartTechnology™
01/12/2024
Siemens Healthineers and DeepHealth have signed a letter of intent to create AI-powered SmartTechnology™ to improve patient experience and operational efficiency in ultrasound. The collaboration aims to facilitate [...]
Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia
01/12/2024
– Les données intermédiaires d’une étude de phase II portant sur le pétosemtamab administré à une dose de 1 500 mg en monothérapie continuent de démontrer une activité cliniquement significative dans le traitement de 2 [...]
Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024
01/12/2024
– Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate clinically meaningful activity in 2L+ HNSCC – Conference call on Saturday, Dec. 7 at 9:00 a.m. ET to discuss full data set UTRECHT, The [...]
Philips optimizes CT workflows with in-house AI, launches CT 5300 in North America at #RSNA2024
01/12/2024
December 1, 2024 Philips CT 5300 combines innovative hardware, software, and artificial intelligence to make high-quality screening, diagnostic, and interventional imaging accessible to more patients, including reading [...]
Rakovina Therapeutics Announces 2024 Q3 Financial Results and Provides Corporate Update
30/11/2024
All dollar amounts reflected in Canadian dollars unless otherwise stated VANCOUVER, British Columbia, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company [...]
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
29/11/2024
BOSTON, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease [...]
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
29/11/2024
BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today [...]
CorVel Announces Retirement of V. Gordon Clemons
29/11/2024
FORT WORTH, Texas, Nov. 29, 2024 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) announces V. Gordon Clemons is electing to retire as a member of the Company’s Board of Directors (the “Board”) and as Chairman of [...]
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29/11/2024
SAN FRANCISCO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies [...]
PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance
29/11/2024
PETACH TIKVA, Israel, Nov. 29, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received [...]
Fate Therapeutics Announces Leadership Transition
29/11/2024
Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025 Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies SAN DIEGO, Nov. 29, 2024 [...]
Apogee Therapeutics Announces Agenda for Virtual R&D Day
29/11/2024
SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy [...]
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
29/11/2024
COPENHAGEN, Denmark, November 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial [...]
Narayana Health Issues Statement Regarding Spire Healthcare Group plc Under Rule 2.8 of the Takeover Code
29/11/2024
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH [...]
CORRECTION: RadNet’s DeepHealth Subsidiary Expands FDA Clearance for SmartMammo™ Solution
29/11/2024
SmartMammo™’s AI algorithm now FDA cleared with GE HealthCare’s Senographe Pristina™, expanding access to enhanced cancer detection. The clearance enables RadNet’s DeepHealth and GE HealthCare collaboration to bring [...]
Eurobio Scientific : succès de l’OPA à l’issue de sa première période, réouverture de l’offre du 4 au 17 décembre
29/11/2024
Eurobio Scientific : succès de l’OPA à l’issue de sa première période, réouverture de l’offre du 4 au 17 décembre Paris, le 29 novembre 2024 – 15H30 Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME) et EB [...]
Major shareholder announcement
29/11/2024
Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and [...]
Mainz Biomed Announces Stock Split
29/11/2024
BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. ( NASDAQ:MYNZ ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of [...]

Pages